Product Images Celecoxib

The text contains information about capsules containing 100 mg of celecoxib, stored at room temperature between 15°C to 30°C (69°F to 86°F). It also mentions to dispense in child-resistant containers and has Rx Only status. The capsules are from an FDA-approved pharmaceutical company.*

This is a description for a medication called Celecoxib in capsule form with 100 mg strength. The pharmacist should dispense a Medication Guide with each capsule to the patients. The medication should be stored at room temperature between 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F). The prescribing information should be consulted for dosage and usage instructions. The capsules should be dispensed in child-resistant containers. The medication is manufactured by AiPing Pharmaceutical in Hauppauge, NY. Further details can be found on their website.*

This is a description for the medication "Celecoxib Capsules 200 mg". Each capsule contains 200 mg of celecoxib and should be dispensed in light-resistant containers. It is manufactured for AiPing Pharmacetical, Inc. and the dosage and usage instructions can be found in the accompanying prescribing information. The medication should be stored at room temperature with excursions permitted between 15°C to 30°C. For more information, a medication guide can be printed from the website: aipingpharmaceutical.com/products.*

This is a description of Celecoxib capsules containing 200 mg of the active ingredient. The medication is dispensed in child-resistant containers and should be stored at room temperature. The text provides information for pharmacists to dispense the capsules and refers to prescribing information for dosage and use instructions. The manufacturer is AiPing Pharmaceutical, based in Hauppauge, NY. The prescription is for 500 capsules. The text also includes a reference to a medication guide available online.*

Each capsule contains 400 mg of celecoxip. It is recommended to store them at room temperature between 20°C to 25°C (68°F to 77°F) in child-resistant containers. The dosage and use should be handled according to USP Controlled Room Temperature guidelines. These capsules are manufactured by AlPing Pharmaceutical, Inc. For more information, visit their website: https://alpingpharmaceutical.com/products.*

The text provides information about a medication in capsule form, specifically Celecoxib Capsules. It should be stored at room temperature between 20°C to 25°C. Excursions are permitted between 15°C to 30°C. The capsules should be dispensed according to USP guidelines and should be kept in child-resistant containers. Instructions for use and more details can be found at the website "shippingpharmaceuticalproducts." The product's NDC number is 11788-112-60, and it contains 60 capsules. The text also shows the company name as "AiPing" and the location as Hauppauge, NY 11788, with a prescription requirement.*

This is a comparison of side effects associated with Celecoxib (400 to 800 mg daily) and Placebo. The table shows the percentage occurrence of specific side effects such as diarrhea, gastroesophageal reflux disease, nausea, vomiting, dyspnea, hypertension, and nephrolithiasis in a study with 2285 participants receiving Celecoxib and 1303 participants receiving Placebo. The results highlight the differences in the incidence rates of these adverse events between the two groups.*

This is a list of adverse events occurring in 2% of patients who were taking Celecoxib in pre-marketing controlled arthritis trials. The table displays percentages of different side effects such as gastrointestinal issues, body pain, nervous system reactions, psychiatric symptoms, respiratory problems, and skin reactions among others. Each percentage is compared between patients taking Celecoxib, placebo, Naproxen, Diclofenac, and 1-Butyl-10-gBenzoguanidine (1BU). The text provides an insight into the occurrence of adverse events in patients using these medications.*

This is a detailed table outlining adverse events occurring in over 5% of Juvenile Rheumatoid Arthritis patients across different treatment groups. It provides valuable information on the frequency of various adverse events such as eye disorders, gastrointestinal issues, infections, musculoskeletal problems, and respiratory symptoms among others. Additionally, it includes data on laboratory test abnormalities observed in the patients.*